C. Gaich

Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis

Peter C. Taylor, Edward Keystone, Désirée van der Heijde et al. · New England Journal of Medicine · 2017 · 951 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study

Maxime Dougados, Désirée van der Heijde, Ying‐Chou Chen et al. · Annals of the Rheumatic Diseases · 2016 · 399 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +17

A randomized phase 2b trial of baricitinib, an oral Janus kinase (<scp>JAK</scp>) 1/JAK2 inhibitor, in patients with moderate‐to‐severe psoriasis

Kim Papp, Alan Menter, Maitreyi Raman et al. · British Journal of Dermatology · 2016 · 258 citations · Full text

Medicine, Dermatology, Pharmacology +13

Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study

Edward Keystone, Peter C. Taylor, Yoshiya Tanaka et al. · Annals of the Rheumatic Diseases · 2017 · 121 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +17

Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON)

Josef S Smolen, Joel M. Kremer, C. Gaich et al. · Annals of the Rheumatic Diseases · 2016 · 115 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +17